Skip to main content
SpringerLink
Log in

Aktueller Stand der oralen Therapie mit immunmodulatorischen und immunsuppressiven Medikamenten

Current status of oral immunomodulatory and immunosuppressive agents

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Zahlreiche dermatologische Krankheiten sind auf angeborene oder erworbene Fehlregulationen des Immunsystems zurückzuführen. Immunmodulierende sowie immunsupprimierende Agenzien spielen daher eine bedeutende Rolle in der dermatologischen Therapie. Andererseits haben verschiedene Studien eine Unterversorgung von systemischen Therapieansätzen bei Erkrankungen wie der atopischen Dermatitis oder der Psoriasis vulgaris festgestellt. Unter Beachtung der Nebenwirkungen und Medikamenteninteraktionen stellen diese Medikamente jedoch sichere und effektive Behandlungsoptionen dar. Im Folgenden möchten wir daher eine Übersicht über die wichtigsten oralen Immunsuppressiva bzw. Immunmodulatoren, ihrer Wirkmechanismen, Indikationen und unerwünschten Arzneimittelwirkungen sowie Neuerungen und therapeutische Perspektiven geben. Intravenös oder subkutan zu verabreichende Biologika werden in diesem Review nicht berücksichtigt.

Abstract

Various dermatological disorders require treatments with immunosuppressive or immunomodulatory agents. Nevertheless, several studies demonstrate low prescription rates for systemic treatments. This low usage may be a result of physicians’ low levels of confidence in administering systemic treatments. However, immunosuppressive treatments represent safe options when potential side effects as well as pharmacological interactions are considered. This review overviews the most important oral immunosuppressive or immunomodulatory agents and summarizes their mode of actions, indications, and adverse effects. Biologics that require intravenous or subcutaneous application are not included, but novel and new agents likely to be released soon are considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Nast A, Reytan N, Rosumeck S et al (2008) Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 22:1337–1342

    Article  CAS  PubMed  Google Scholar 

  2. Langenbruch A, Radtke M, Franzke N et al (2013) Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol [Epub ahead of print]

  3. Nast A, Erdmann R, Pathirana D, Rzany B (2008) Translating psoriasis treatment guidelines into clinical practice – the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract 14:803–806

    Article  PubMed  Google Scholar 

  4. Hench PS, Kendall EC et al (1949) The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24:181–197

    CAS  PubMed  Google Scholar 

  5. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 353:1711–1723

    Article  CAS  PubMed  Google Scholar 

  6. Song IH, Gold R, Straub RH et al (2005) New glucocorticoids on the horizon: repress, don’t activate! J Rheumatol 32:1199–1207

    CAS  Google Scholar 

  7. Joshi N, Rajeshwari K (2009) Deflazacort. J Postgrad Med 55:296–300

    Article  CAS  PubMed  Google Scholar 

  8. Olgaard K, Storm T, Wowern N van et al (1992) Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 50:490–497

    Article  CAS  PubMed  Google Scholar 

  9. Buttgereit F, Doering G, Schaeffler A et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371:205–214

    Article  CAS  PubMed  Google Scholar 

  10. Sporl F, Korge S, Jurchott K et al (2012) Kruppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes. Proc Natl Acad Sci U S A 109:10903–10908

    Article  PubMed Central  PubMed  Google Scholar 

  11. Buttgereit F, Burmester GR, Lipworth BJ (2005) Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365:801–803

    Article  CAS  PubMed  Google Scholar 

  12. Borel JF, Feurer C, Gubler HU, Stahelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6:468–475

    Article  CAS  PubMed  Google Scholar 

  13. Rosenbach M, Hsu S, Korman NJ et al (2010) Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 62:655–662

    Article  CAS  PubMed  Google Scholar 

  14. Wolff K, Schreiner E (1969) Immunosuppressive therapy of pemphigus vulgaris. Preliminary results of azathioprine (Imuran) treatment). Arch Klin Exp Dermatol 235:63–77

    Article  CAS  PubMed  Google Scholar 

  15. Tiede I, Fritz G, Strand S et al (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–1145

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Patel AA, Swerlick RA, McCall CO (2006) Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 55:369–389

    Article  PubMed  Google Scholar 

  17. Bidinger JJ, Sky K, Battafarano DF, Henning JS (2011) The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome. J Am Acad Dermatol 65:184–191

    Article  CAS  PubMed  Google Scholar 

  18. Mitsui A, Suzuki S (1969) Immunosuppressive effect of mycophenolic acid. J Antibiot (Tokyo) 22:358–363

    Google Scholar 

  19. Beissert S, Mimouni D, Kanwar AJ et al (2010) Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 130:2041–2048

    Article  CAS  PubMed  Google Scholar 

  20. Kofler S, Wolf C, Shvets N et al (2011) The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant 30:565–571

    Article  PubMed  Google Scholar 

  21. Wozel VE (2010) Innovative use of dapsone. Dermatol Clin 28:599–610

    Article  CAS  PubMed  Google Scholar 

  22. Lorenz M, Wozel G, Schmitt J (2012) Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 92:194–199

    Article  PubMed  Google Scholar 

  23. Gurcan HM, Ahmed AR (2009) Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 10:383–396

    Article  PubMed  Google Scholar 

  24. Mrowietz U, Asadullah K (2005) Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 11:43–48

    Article  CAS  PubMed  Google Scholar 

  25. Ghoreschi K, Bruck J, Kellerer C et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291–2303

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Shen S, O’Brien T, Yap LM et al (2012) The use of methotrexate in dermatology: a review. Australas J Dermatol 53:1–18

    Article  PubMed  Google Scholar 

  27. Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33–39

    Article  CAS  PubMed  Google Scholar 

  28. Montesinos MC, Takedachi M, Thompson LF et al (2007) The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5’-nucleotidase: findings in a study of ecto-5’-nucleotidase gene-deficient mice. Arthritis Rheum 56:1440–1445

    Article  CAS  PubMed  Google Scholar 

  29. Chalmers RJ, Kirby B, Smith A et al (2005) Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 152:444–450

    Article  CAS  PubMed  Google Scholar 

  30. Ghoreschi K, Gadina M (2014) JAKpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol 23:7–11

    Article  CAS  PubMed  Google Scholar 

  31. O’Shea JJ, Kontzias A, Yamaoka K et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii111–ii115

    Google Scholar 

  32. O’Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542–550

    Article  Google Scholar 

  33. Mamolo C, Harness J, Tan H, Menter A (2013) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol [Epub ahead of print]

  34. Ports WC, Khan S, Lan S et al (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169:137–145

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. S. Meller, A.M. Baran, S.A. Braun, N. Klossowski und B. Homey geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Department of Dermatology, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    S. Meller, A.M. Baran, S.A. Braun, N. Klossowski &  B. Homey

Authors
  1. S. Meller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.M. Baran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S.A. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Klossowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Homey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Homey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meller, S., Baran, A., Braun, S. et al. Aktueller Stand der oralen Therapie mit immunmodulatorischen und immunsuppressiven Medikamenten. Hautarzt 65, 89–97 (2014). https://doi.org/10.1007/s00105-013-2652-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-013-2652-8

Schlüsselwörter

Keywords

Search

Navigation